The Role of Helicobacter pylori in Patients with Hypothyroidism in Whom Could Not be Achieved Normal Thyrotropin Levels Despite Treatment with High Doses of Thyroxine
Abstract
Background: Helicobacter pylori infection is a most frequent cause of chronic gastritis. H. pylori may decrease absorption of oral thyroxine by decreasing gastric acid secretion in the stomach. In this study, we aimed to investigate the change in thyroid function tests of the cases after H. pylori eradication who were not responding to high doses of thyroxine treatment before H. pylori eradication. Methods: Hypothyroid cases who were not responding to high doses of thyroxine among the ones presented to Endocrinology and Gastroenterohepatology Clinics of Sisli Etfal Training and Research Hospital between 2009 and 2010 were included in the study. Thyroid function tests were performed two times in all cases before and after H. pylori eradication. Duodenal, antral and corporal biopsies, and jejunal aspirates and biopsies were taken during upper gastrointestinal system endoscopies performed in all patients. Cases without intestinal pathology were included in the study. Results: Serum thyrotropin (TSH), free T3, and free T4 values before H. pylori eradication were 30.5 ± 28.8 IU/mL, 2.64 ± 0.56 pg/mL, and 0.92 ± 0.32 ng/mL, respectively, and after eradication were found to be 4.2 ± 10.6 IU/mL, 3.02 ± 0.61 pg/mL, and 1.3 ± 0.34 ng/mL, respectively (p values <.001, .002, and <.001, respectively). After H. pylori eradication treatment, TSH decreased in all of the cases, factitious thyrotoxicosis developed in % 21 of these cases. Conclusion: In hypothyroid cases, H. pylori gastritis may be responsible for an inadequate response to the treatment. H. pylori eradication in the cases receiving high doses of thyroxine has a risk for thyrotoxicosis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment of H. pylori was associated with reduction of serum TSH from 30.5 to 4.2 mIU/L in patients nonresponsive to high-dose LT4.
“In a prospective, nonrandomized study treatment of H. pylori was associated with reduction of serum TSH levels from 30.5 to 4.2 mIU/L in patients who were considered nonresponsive to high doses of LT4 (152).”
From Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (2014) · cites this paper as [152]
Cites
Classification and Grading of Gastritis: The Updated Sydney System
Dixon, M. F., Genta, R. M., Yardley, J. H., & Correa, P. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199610000-00001 · Cited by 5,185 · see citing works
Malfertheiner, P., Mégraud, F., O'Morain, C. A., Bazzoli, F., El-Omar, E. M., Graham, D., Hunt, R. H., Rokkas, T., Vakil, N. B., Kuipers, E. J., et al. (2006) · Gut · doi:10.1136/gut.2006.101634 · Cited by 2,242 · see citing works
Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma
Wotherspoon, A. C. (1991) · The Lancet · doi:10.1016/0140-6736(91)92035-z · Cited by 1,862 · see citing works
Long-term sequelae of Helicobacter pylori gastritis
Kuipers, E. J., Peña, A. S., Festen, H. P. M., Meuwissen, S. G. M., Uyterlinde, A. M., Roosendaal, R., Pals, G., & Nelis, G. F. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91084-0 · Cited by 767 · see citing works
Kuipers, E. J., Lundell, L. R., Klinkenberg–Knol, E. C., Havu, N., Festen, H. P. M., Liedman, B., Lamers, C. B. H. W., Jansen, J. B. �. �., Dalenbäck, J., Snel, P., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604183341603 · Cited by 764 · see citing works
Helicobacter pylori infection and chronic gastric acid hyposecretion
El-Omar, E. M., Oien, K. A., El-Nujumi, A., Gillen, D., Wirz, A. A., Dahill, S., Williams, C., Ardill, J., & MCCOLL, K. E. L. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70075-1 · Cited by 642 · see citing works
Fish, L. H., Schwartz, H. L., Cavanaugh, J., Steffes, M. W., Bantle, J. P., & Oppenheimer, J. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198703263161302 · Cited by 353 · see citing works
HELICOBACTER PYLORI AND GASTRIC CANCER
Parsonnet, J. (1993) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(21)00265-x · Cited by 346 · see citing works
Thyroxine in Goiter, <i>Helicobacter pylori</i> Infection, and Chronic Gastritis
Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Fave, G. D., & Annibale, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043903 · Cited by 329 · see citing works
El-Omar, E. M., Penman, I. D., Dorrian, C. A., Ardill, J. E. S., & MCCOLL, K. E. L. (1993) · Gut · doi:10.1136/gut.34.8.1060 · Cited by 255 · see citing works
Effect of calcium carbonate on the absorption of levothyroxine
Singh, N. (2000) · JAMA · doi:10.1001/jama.283.21.2822 · Cited by 219 · see citing works
Relationship between gastric secretion and infection.
Howden, C. W., & Hunt, R. H. (1987) · Gut · doi:10.1136/gut.28.1.96 · Cited by 209 · see citing works
Duodenal bacterial overgrowth during treatment in outpatients with omeprazole.
Fried, M., Siegrist, H. H., Frei, R., Froehlich, F., Duroux, P., Thorens, J.-J., Blum, A. L., Billé, J., Gonvers, J. J., & Gyr, K. E. (1994) · Gut · doi:10.1136/gut.35.1.23 · Cited by 200 · see citing works
The Gastric Biology ofHelicobacter pylori
Sachs, G. M., Weeks, D. L., Melchers, K., & Scott, D. R. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142156 · Cited by 158 · see citing works
Association between hypothyroidism and small intestinal bacterial overgrowth
Lauritano, E. C., Bilotta, A. L., Gabrielli, M., Scarpellini, E., Lupascu, A., Laginestra, A., Novi, M., Sottili, S., Serricchio, M., Cammarota, G., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0606 · Cited by 140 · see citing works
Helicobacter pylori Infection Is Markedly Increased in Patients With Autoimmune Atrophic Thyroiditis
de Luis, D. A., Varela, C., de la Calle, H., et al. (1998) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199806000-00008 · Cited by 129 · see citing works
Annibale, B., Aprile, M. R., D′ambra, et al. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00752.x · Cited by 123 · see citing works
Gastrointestinal Transit in Thyroid Disease
Shafer, R. B., Prentiss, R. A., & Bond, J. H. (1984) · Gastroenterology · doi:10.1016/s0016-5085(24)05134-5 · Cited by 116 · see citing works
Helicobacter pylori infection and endocrine disorders: Is there a link?
Papamichael, K. X., Papaioannou, G., Karga, H., et al. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2701 · Cited by 111 · see citing works
Sucralfate causes malabsorption of L-thyroxine
Sherman, S. I., Tielens, E. T., & Ladenson, P. W. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90093-0 · Cited by 105 · see citing works
Capurso, G., Lahner, E., Marcheggiano, A., Caruana, P., Carnuccio, A., Bordi, C., Fave, G. D., & Annibale, B. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01101.x · Cited by 90 · see citing works
Figura, N., Cairano, G. D., Loré, F., et al. (1999) · PubMed · Cited by 79 · see citing works
Systematic review: Heliocobacter pylori infection and impaired drug absorption
Lahner, E., Annibale, B., & Fave, G. D. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03906.x · Cited by 71 · see citing works
Early events in proton pump inhibitor‐associated exacerbation of corpus gastritis
Graham, D. Y., Opekun, A. R., Yamaoka, Y., Osato, M. S., & El-Zimaity, H. M. T. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01400.x · Cited by 51 · see citing works
Tomasi, P. A., Dore, M. P., Fanciulli, G., et al. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-1615-z · Cited by 39 · see citing works
Helicobacter pylori Infection in Patients with Hashimoto's Thyroiditis
Franceschi, F., Satta, M. A., Mentella, M. C., et al. (2004) · Helicobacter · doi:10.1111/j.1083-4389.2004.00241.x · Cited by 35 · see citing works
Helicobacter pylori inflammation and immunity
Nedrud, J. G., Blanchard, S. S., & Czinn, S. J. (2002) · Helicobacter · doi:10.1046/j.1523-5378.7.s1.4.x · Cited by 30 · see citing works
Triantafillidis, J. K., Georgakopoulos, D., Gikas, A., et al. (2003) · PubMed · Cited by 26 · see citing works
Is the Sensitivity to Gastric Acid Inhibition Helicobacter pylori Status-Dependent?
Smout, A. J. P. M. (1998) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655298750027191 · Cited by 18 · see citing works
Thyroxine in Goiter,H. pyloriInfection, and Gastritis
Dietrich, J. W., & Boehm, B. O. (2006) · New England Journal of Medicine · doi:10.1056/nejmc061447 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · see citing works
“2 mIU/L in patients who were considered nonresponsive to high doses of LT4 (152).”
A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism
Colucci, P., Yue, C. S., Ducharme, M., Benvenga, S., Principal Scientist, L. A. C. I., Principal Scientist, L. A. C. I. A. P. C., President and CEO, L. A. C. I., & Professor of Medicine, D. (2010) · European Endocrinology · doi:10.17925/ee.2013.09.01.40 · Cited by 167 · see citing works
Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review
Skelin, M., Lucijanić, T., Amidžić Klarić, D., Rešić, A., Bakula, M., Liberati-Čizmek, A.-M., Gharib, H., & Rahelić, D. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.005 · Cited by 133 · see citing works
Caron, P., Grunenwald, S., Persani, L., Borson-Chazot, F., Leroy, R., & Duntas, L. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09691-9 · Cited by 53 · see citing works
Levothyroxine therapy in gastric malabsorptive disorders
Virili, C., Brusca, N., Capriello, S., & Centanni, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.621616 · Cited by 52 · see citing works
Seeking optimization of LT4 treatment in patients with differentiated thyroid cancer
Stramazzo, I., Capriello, S., Antonelli, A., Fallahi, P., Centanni, M., & Virili, C. (2022) · HORMONES · doi:10.1007/s42000-022-00376-9 · Cited by 9 · see citing works
Oteri, V., Volpe, S., Lopes, M., Sceusa, G., Tumminia, A., Belfiore, A., Frasca, F., & Gullo, D. (2024) · Endocrine · doi:10.1007/s12020-024-04016-7 · Cited by 9 · see citing works
Caron, P., Tudor, C., & Grunenwald, S. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf017 · Cited by 7 · see citing works
“It is well known that gastric acid pH plays an important role in levothyroxine absorption, and an increased gastric pH decreases the solubility of levothyroxine tablets and can potentially impair absorption of orally administered levothyr-oxine sodium [2, 5, 25, 26].”
A case of H. pylori infection presenting as refractory hypothyroidism
Gupta, P., Johnson, J. T., Soumya, S. L., Cherian, K. E., Kapoor, N., & Paul, T. V. (2020) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_729_20 · Cited by 6 · see citing works
Levothyroxine absorption test—results and follow up of patients from a single center
Subramaniam, K., Babu, T., Sreevalsan, K. C., & Mathew, S. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_188_21 · Cited by 4 · see citing works
- Authors
- Bugdaci, M. S., Zuhur, S. S., Sokmen, M., Toksoy, B., Albayrak, B., & Altuntas, Y.
- Affiliations
- Şişli Etfal Eğitim ve Araştırma Hastanesi (TR)
- ORCID
- Zuhur, Sayid Shafi
- Venue
- Helicobacter
- Publisher
- Wiley
- Published
- 2011-03-16
- Volume
- 16
- Issue
- 2
- Pages
- 124-130
- ISSN
- 1083-4389 (ISSN-L)
- 1523-5378
- OpenAlex
- W1938905730
- Cited by
- 41
- References
- 30
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 9 · 2021: 3 · 2020: 3 · 2019: 1 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 5 · 2013: 2 · 2012: 3
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Helicobacter (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Helicobacter pylori-related gastroenterology studies
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- Helicobacter pylori, hypothyroidism, thyroid-stimulating hormone, Helicobacter pylori eradication, gastric acid secretion, thyroid function tests, chronic gastritis
- MeSH terms
- Adult, Amoxicillin, Drug Therapy, Combination, Female, Gastritis, Humans, Hypothyroidism, Male, Metronidazole, Middle Aged, Tetracycline, Thyrotropin, Thyroxine, Triiodothyronine, Helicobacter Infections, Clarithromycin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
